DNA Sequences & Gene Patents
Author: LawSphereX
Category: Intellectual Property
Published:
Updated:
DNA SEQUENCES & GENE PATENTS
Tirth Acharya, Unitedworld School of Law, Karnavati University, Gandhinagar Dr. Aseem Chandra Paliwal [Asst. Professor], Unitedworld School of Law, Karnavati University, Gandhinagar
ABSTRACT
The intersection of biotechnology and intellectual property law has given rise to controversial discussions related to gene patenting in ethical, legal, and commercial terms. This text will look into the advancements made in the area of DNA sequencing followed by gene patents, reflecting on the growth of these gene patents from key scientific breakthroughs to main legal cases, including Diamond v. Chakrabarty and Association for Molecular Pathology v. Myriad Genetics. It further sketches the different genres under which gene patents fall: disease gene, composition of matter, and functional use while at the same time surveying the world legal landscape in focus and contrasting the United States with EU and India in terms of approach.
This paper examines how gene patents stimulate innovation and attract investments, particularly in biotechnology and pharmaceutical industries, and at the same time open them to monopolizing very important genetic data, restricting research, and inflating the cost of healthcare. The paper presents natural and altered genetic sequences as well as the bioethical dilemmas and socioeconomic implications accompanying gene ownership. It advocates the creation of a balanced legal framework facilitating advancement in science without compromising equitable access to genetic therapies and diagnostics. This paper, through critical analysis, calls for global harmonization of gene patent laws, bringing about greater transparency in licensing and inclusive biotech development for the public good.
Introduction
DNA sequencing is the standard laboratory method for determining the precise arrangement of bases in a DNA molecule, which encodes the biological data that cells need to grow and function. 1 This process has been significantly impacted by technological advancements, making the information in our genomes more widely accessible. Genes are the fundamental structural and functional unit of heredity, with DNA being the building block of genes. The Human Genome Project aimed to sequence every human DNA molecule between 1990 and 2003, resulting in between 20,000 and 25,000 genes that give instructions on how to make proteins. Alleles are strains of the same gene that change slightly in their DNA base sequence. 2 Watson and Crick's theory on the double helix structure of DNA in 1953 set the groundwork for modern genetics.
Two decades later, Cohen, Boyer, and Chang created a method that allowed for the transfer of DNA segments from one living form to another, creating the first "recombinant organism. " This development allowed scientists to introduce genetic features into other species for the first time. Genettech Inc. , founded in 1976, began to commercialize genetic technology, with the first human gene protein produced in a bacterium announced in
1977. Sanger's discovery of a technique for reading DNA sequences in 1977 marked a second
significant advance in genetics, allowing scientists to understand the evolutionary and functional links between genes and the genetic mutations that cause human disease. The creation of PCR in the 1980s eliminated the need for microorganism cloning by offering a rapid and simple technique for selectively amplifying DNA fragments. Hoffman-LA Roche Inc. (Roche) now owns over 130 patents pertaining to the PCR procedure, making access to the patent technology essential for almost all genetic laboratory work. The commercialization of genetic inventions has led to legal and ethical concerns in the biotechnology sector. 3The 1980 ruling in Diamond v. Chakrabarty 4established that biological forms are patentable subject matter under US law, allowing a patent to be issued for a recombinant bacteria.
The Bayh-Dole Act, passed by the US Congress that same year, stipulates that organizations doing the study are the exclusive owners of intellectual property rights resulting from publicly funded research.
1 National Human Genome Research Institute, Data on Genome, National Human Genome Research Institute
(NHGRI) (2020), https://www.genome.gov/ (last visited Jan 7, 2025). Leslie Biesecker, Allele, National Human Genome Research Institute (2022), https://www.genome.gov/genetics-glossary/Allele (last visited Jan 7, 2025). 3 A brief history of gene patents, ALRC, https://www.alrc.gov.au/publication/genes-and-ingenuity-genepatenting-and-human-health-alrc-report-99/3-gene-patents/a-brief-history-of-gene-patents/ (last visited Jan 7, 2025).
4 Diamond v Chakrabarty 447 US 303 (1980)
This legislation aimed to promote innovation and exploitation. The biotechnology sector grew rapidly in the 1980s, with the FDA approving the first medication to be produced and sold by a biotechnology business in 1985. The Californian Institute of Technology and Applied Biosystems Inc. introduced an automated DNA fluorescence sequencer in 1986, leading to advancements in sequencing techniques. The first American patent for a whole animal was awarded to the "Harvard Mouse" in 1988, raising concerns regarding the morality of patenting higher life forms. The Human Genome Project's launch in 1990 marked the success of genetic research at the time. In February 2001, the Human Genome Project and the Celera Genomics Group released the working draft of the human genome sequence, ushering in a new age of genomics. In April 2003, the human genome's final sequencing was finished.
Gene patenting has not always been an issue of black and white. On one hand, patents can encourage innovations, pushing researchers and biotech companies to develop ground-breaking treatments and cures. On the other hand, they can stifle scientific progress, create monopolies, and put life-saving tests out of reach for millions. Different countries have taken different approaches to gene patenting. Through key case studies, such as the fight over CRISPR technology and the controversy around BRCA gene patents, the real-world consequences of gene patenting can be explored. The question remains: how shall the world strike a balance between promoting innovation and ensuring that genetic discoveries benefit everyone, not just those who can afford expensive treatments and cures?
Concept of Biotechnology and gene patents: Biotechnology has rapidly evolved, combining technological advancements and biological sciences to create innovative products and processes. 5 The manipulation of organisms at various levels, from molecular to genetic, has led to breakthroughs in areas such as industrial manufacturing, environmental management, agriculture, and medicine. Genetic research, particularly genetic research, involves studying DNA sequences to understand their functions and potential uses. This led to the introduction of gene patenting, a form of intellectual property that grants proprietary rights over a specific DNA sequence. Gene patenting allows the holder to exclude others from using, producing, or selling the patented genetic material for 20 years.
Different jurisdictions have different patenting requirements for genes, but generally, a patentable gene is the product of human intervention. A patentable gene must be proven that 5 Sarah Lewis & Nick Barney, What is biotechnology (biotech)? - Definition from WhatIs. com, WhatIs. com (2019), https://www. techtarget. com/whatis/definition/biotechnology (last visited Feb 23, 2025). the DNA sequence can be used in industry, has newfound function, and is inventive over known prior art. Gene patenting has been instrumental in promoting the participation of businesses and academic institutions in genetic research in the biotechnology sector, developing genetically modified crops, improved diagnostic tests, and gene-based medicines. Gene patents have become essential to biotechnology despite legal confrontations across different nations.
In the US, patents are granted after being examined by a patent agency, such as the US Patent and Trademark Office, Indian Patent Office, or the European Patent Office. The examination process ensures that inventions meet the requirements for patentability and that the patent only protects what has been invented. Broad claims to inventions like polymerase chain reaction (PCR), recombinant technologies, gene knockout techniques, and specific gene sequences can often be given broad claims. However, these claims are fundamental and difficult to get past, and any advancements likely need licenses before they can be used for profit. Gene patents grant the exclusive right to create, utilize, market, and import a molecule with a claimed sequence. Understanding an organism's genome's DNA sequence yields important scientific data that may pave the way for further research.
Gene patents consist of three categories: diagnostic, composition matter, and functional use. Genetic inventions fall under three categories: • Disease gene patents, • Composition of matter, and • Functional use. Disease gene patents assert the characterization of a person's genetic composition at a diseaseassociated locus for diagnosis or prognosis. 6These patents cover all known testing techniques, including hybridization, Southern analysis, PCR, and DNA chips. Genes linked to ovarian and breast cancers (BRCA1 and BRCA27), colon cancers (HNPCC, FAP), hemochromatosis (HFE), cystic fibrosis (CFTR), and an increasing number of neurological conditions such as 6 JF Merz et al. , Disease Gene Patenting Is a Bad Innovation, 2 Molecular diagnosis: a journal devoted to the understanding of human disease through the clinical application of molecular biology 299 (1997), https://pubmed. ncbi. nlm.
nih. gov/10462622/ (last visited Jan 17, 2025). 7 National Cancer Institute, BRCA Mutations: Cancer Risk & Genetic Testing, National Cancer Institute (2024), https://www. cancer. gov/about-cancer/causes-prevention/genetics/brca-fact-sheet (last visited Feb 23, 2025). late-onset Alzheimer's disease (Apo-E), Canavan disease, Charcot-Marie-Tooth disease (CMT- 1A, CMT-X), spinal muscular atrophy (SMN1), and spinocerebellar ataxia (SCA1–12). 8 Clinical molecular diagnostics labs have not been the target of a vigorous enforcement effort by the owners of the vast majority of issued gene patents. However, there are few instances when patent owners have declined to authorize labs to conduct particular tests. Only commercial laboratories often offer testing for a variety of neurological illnesses (Athena Diagnostics) and genes linked to breast and ovarian cancer (Myriad Genetics).
Composition of matter includes the isolated and purified gene (cDNA) and all derivative products (such as recombinant proteins or drugs, viral vectors and gene transfer "therapies," transfected cells, cell lines, and higher order animal models in which the patented gene has been inserted or knocked out). A wide range of chemicals and technologies are covered under patents on human genetic compositions of matter. Functional use claims assert methods and material compositions (usually referred to as "small molecule" medications) that are used to up- or down-regulate the gene, based on the discovery of the role genes play in disease or other physiological and cellular activities or pathways. These medications are probably not gene products but rather other kinds of chemicals that have been shown to affect how genes work.
They are also probably patentable as distinct chemical entities that can be used as treatments. For example, a recently invalidated patent claimed materials and techniques for selectively inhibiting the Cox-2 gene, which inhibits pain and inflammation. The patent in question addressed the mechanism of action for three medications that eventually reached the market: Merck's Vioxx, Pfizer's Bextra, and Celebrex, co-marketed by Pharmacia, which is part of Searle. The Cox-2 patent aimed to encompass all medications that operate by modifying the function of a specific target gene. Each of these chemical entities can still be patented individually as novel, non-obvious, and beneficial treatments for pain and inflammation. Understanding that naturally existing genes form modified genetic sequences is one of the most essential parts of gene patenting.
This distinction hugely determines the legal frameworks, research incentives, and public access to genetic developments as it defines whether a genetic discovery can be copyrighted. While modified genetic sequences had some degree of human 8 Sirpa Soini, Ségolène Aymé & Gert Matthijs, Patenting and licensing in genetic testing: ethical, legal and social issues, 16 European Journal of Human Genetics (2008). (Last visited Jan 17, 2025). intervention to change their structure or function, genes occurring in nature exist in their original biological form.
1 Natural genes
These are genetic sequences in living organisms that are not artificially altered. They perform functions such as encoding proteins and regulating biological processes in all organisms that naturally evolved with those genes. Members of a species share them, and they serve as a blueprint for life. Most jurisdictions do not permit patents on naturally occurring genes because they are thought to be discoveries and not inventions. It has been held by courts that genes in their natural state, i. e. , isolated from other cellular components, are products of nature and are not available for monopoly of further use. The landmark Association for Molecular Pathology v. Myriad Genetics (2013)9 case ruled that genes occurring in nature, even if isolated from the body, cannot be patented. The U. S.
Supreme Court reasoned that extracting a gene from the body does not create something new, as the sequence remains unchanged. EU law is slightly more flexible than U. S. law. Under the Biotechnology Directive (98/44/EC)10, a naturally occurring gene can be patented only if an applicant demonstrates a specific industrial application, such as its use in producing a diagnostic test or therapeutic product. India stands firm in opposition to patenting genes and other naturally existing materials. Any living or non-living substance found in nature cannot be patented, according to Section 3(c) of the Indian Patents Act (1970). Many contend that since naturally occurring genes are a component of the human genome, they need to be regarded as a shared heritage and kept open for use in study and medicine.
Natural gene patenting may result in monopolies on diagnostic procedures and therapies, limiting patient access and driving up medical expenses.
2 Modified Genetic Sequences
These include synthetically manufactured DNA, such as cDNA, recombinant DNA, or genetically modified sequences, which do not exist in nature. They usually qualify for patent protection in all three jurisdictions since they entail human intervention. The Myriad decision made it clear that although genes found in nature cannot be patented, cDNA and other synthetic changes can because they are not found in nature. Modified DNA sequences may be patented under the EPC and
9 Assoc. for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)
10 Directive - 98/44 - EN - EUR-Lex, Europa.eu (2025), https://eur-lex.europa.eu/eli/dir/1998/44/oj/eng (last visited Feb 25, 2025).
Biotechnology Directive as long as they satisfy the requirements for industrial applicability, inventive step, and novelty. Although gene patents are prohibited under Indian patent law, a genetic change may be given a patent if it shows a substantial technological development or industrial purpose. To incentivize biotechnology companies to invest in research on human genetics to foster further gene therapy applications in the agricultural and medical arenas, altered genes are patented. Widespread patents for altered genes, however, may limit the freedom of research, raise the costs of medications, and lead to ethical dilemmas concerning genetic "ownership. " Impacts of granting Gene patents: As an impact of gene patents, scientific and commercial environments of biotechnology and pharmaceutical sectors are very much concerned.
Human DNA sequences normally patented grant exclusive rights to their owners for how the sequences are used in research, diagnosis and treatment development. Patents on genes have encouraged investment and innovation into genetic research but have also raised concerns about the monopolistic and limited access to significant genetic information. 11 The biotechnology and pharmaceutical industries consider the intellectual property to be the pillar upon which innovations rest. There is huge investment and research burden in developing a new medicine or genetic therapy that sometimes span decades. Gene patents entice companies financially by giving them monopoly rights for these discoveries so they can recoup their research and development costs.
Research indicates that, by the year 1999, the USPTO had issued about 3,000 patents referring to human genome sequences, which was an indication of the fast-growing trend of gene patenting in the biomedical research domain. Gene patents are arguably very beneficial for pharmaceutical corporations in making personalized medicine and genetic-based treatments a reality. The identification of genes responsible for diseases, such as BRCA1 and BRCA2 for breast cancer, has paved the way for the development of targeted therapies and diagnostic tools. Companies that own patents on these genes can commercialize the diagnostic tests and therapies, often giving them a competitive edge in the market. Gene patenting affects the financial health of biotech start-ups and associated venture capital investments. Small biotech companies often use gene patents to attract investors.
These patents create a protection framework for the invention. Without this protection, companies may have had problems finding money for long- 11 Frederic M. Scherer, The Economics of Human Gene Patents, 77 Academic Medicine 1348 (2002) (last visited Feb 25, 2025). term research projects. In the United States, the Bayh-Dole Act of 1980 played a critical role in empowering academic institutions and research centers in patenting genetic discoveries and licensing those to biotechnology companies, thus fostering an innovative environment. The patenting of gene is also accused for monopolization because of its role in actually economically advancing medicine. Only a company or organization that has a patent on a human gene has the only right to control how such genes are used in research, diagnosis, or therapy.
This could affect access to genetic tests and scientific collaboration, especially when the prices of the licenses demand exorbitant fees by patent holders. Examples of the most controversial gene patent monopolizations are the patents granted for the BRCA1 and BRCA2 genes owned by Myriad Genetics. The only company meant to provide breast cancer risk assessments imposed very high and short patient accessibility to such assessments. Association for Molecular Pathology v. Myriad Genetics (2013) was a landmark case that went to the U. S. Supreme Court, which found that nature-made DNA sequences may not be patented. Such ruling, however, set the precedent for allowing patents for altered genetic material, including complementary DNA but narrowing the scope of patent monopolization over genes. The dominance of gene patents in developing countries is a very significant concern.
Section 3(d) of the Indian Patent Act prohibits the patenting of genetic material unless substantial therapeutic improvement is shown. This restriction can be an impediment in countries such as India, where accessibility to public healthcare is of utmost importance. The rationale behind this restriction is aimed primarily at preventing monopolies that could inhibit access to reasonably priced genetic testing and therapies. Such monopolisation of genetic resources has ramifications for scientific research, not just for the law. Researchers are often prevented from studying proprietary genes because of having to pay licensing fees and obtaining permission from patent holders. Hence, this may give rise to the 'patent thicket' phenomenon, wherein overlapping patents have created complex legal hurdles, thus obstructing or delaying further scientific advancement.
Gene patenting is a controversial issue that raises bioethical concerns. From utilitarianism, gene patents promote investments in technology and innovations for healthcare and medicine, while deontological perspectives reject the patenting of human genes on moral grounds. The difference between innovation and discovery is another significant ethical consideration in the gene patent debate. The Myriad Genetics case affirmed that ethical difficulties arise when firms or individuals claim ownership over naturally occurring DNA sequences, such as the BRCA1 and BRCA2 genes, which are associated with inherited breast and ovarian cancer. This exclusivity allowed Myriad to price BRCA testing between $3,000 and $4,000, making it unaffordable for many low-income and uninsured individuals. The case became the subject of the landmark U. S. Supreme Court case Association for Molecular Pathology v.
Myriad Genetics (2013), which ruled that naturally occurring genes are not patentable and thus nullified Myriad's patents for DNA sequences found in nature. The Biotech Directive (98/44/EC), which prohibits the patenting of naturally occurring biological material unless isolated and with industrial applicability, presented parallel challenges for Myriad in the EU. Myriad's patents were invalidated in several EU countries, including France and Germany, whereupon public hospitals and research facilities offered BRCA testing at substantially reduced rates. Another clear demonstration of how gene patents impact medical accessibility is the patenting of genes for cystic fibrosis (CF). Researchers at the Hospital for Sick Children in Toronto, Canada, patented the CFTR gene during the 1990s. Mutations in this gene are responsible for cystic fibrosis.
The CF genetic test was monopolized by this patent, which was licensed to one American company. Thus, hospitals and labs were forced to pay exorbitant costs for CF genetic testing because of limited access to the test and blocked research into alternative treatments for CF. The patent owner finally succumbed to pressure, allowing more tests across other labs to be undertaken. India has always been staunchly against gene patents out of concern for medicine and health care accessibility. Section 3(d) of the Indian Patents Act, 1970, which disallows the ever greening of patents, states that genetic material can only be patented upon demonstration of therapeutic efficacy. The application of this principle has gone a long way in preventing monopolization of lifesaving genetic therapies. The case of Glivec (Imatinib Mesylate) brings a significant example.
Novartis claimed that a new version of its leukaemia medication represented a significant advancement and filed a patent application in India. However, the Indian Supreme Court deemed the patent application invalid in 2013 since there was no enhancement of therapeutic efficacy over existing treatments. The ruling enabled Indian pharmaceutical companies to produce and distribute cheap generic copies of Glivec, bringing its prices down from $2600 per month to as low as $200. Similarly, India has blocked attempts by multinational corporations to patent human genes and DNA sequences so that essential medical testing and treatment remain affordable and accessible. Gene patents attract funding for genetic research but may also pose ethical and commercial dilemmas. To correct this imbalance, strict regulations, licensing mechanisms, and promoting open-source biotechnology can be implemented.
Many countries are revising their patent laws to promote private sector investment in biotechnology while ensuring the availability of genetic discoveries for medical purposes. Scientific Innovation vs. Commercial Interest: The debate surrounding the patenting of human genes is a complex one, involving ethics, biotechnology, and intellectual property law. Genes are naturally occurring biological sequences that form the basis of human life and identity, and many argue against patenting, as it raises moral questions about the commodification of human life and creates monopolies over important medical resources. The UNESCO Universal Declaration on the Human Genome and Human Rights of 1997 states that the human genome is humanity's "heritage" and should not be used for profit.
Advocates for this perspective maintain that granting patents on naturally occurring genes establishes unjust monopolies, wherein companies have sole command over the availability of life-saving treatments and tests for the benefit of disadvantaged populations. On the other hand, industry rationale for gene patenting presents a strong argument against the wisdom of the position held by some. Biotech and pharmaceutical companies assert that without patent protection, it becomes commercially untenable to invest in genome sequencing, research into diseases, and the development of genetic medicines. The discovery, isolation, and application of human genes for human therapy entail extensive research and huge financial investments. Without patent protection, companies wonder whether they would even recoup their investments or justify further contributions to genetic medicine.
The World Health Organisation (WHO) warns that excessive patenting would incite growing health inequity worldwide and make genetic treatment a luxury good exclusive to the rich. Myriad Genetics initially sought to price its BRCA test between $3,000 and $4,000 so that patients with neither insurance nor means will be barred from such tests. However, in 2013, the U. S. Supreme Court declared that no patent should militate against the natural occurrence of human genes owing to community pressure and legal battles surrounding this issue, thus increasing competition and reducing the costs of BRCA testing. Proponents of gene patents hold that patents encourage investment in sequencing genomes, personalizing medicine, and genetic medicines by providing monetary incentives.
They argue that private businesses and academic institutions would not be willing to significantly invest in expensive and timeconsuming research if they cannot secure intellectual property rights. However, opponents argue that because exclusive rights inhibit accessibility to genetic sequences, gene patents block research collaboration and hinder scientific advancement. The main problem is the "anticommons effect," where several patents on distinct segments of a gene or associated biological processes erect financial and legal barriers to research. The Myriad case is an example of the effects of gene patents on scientific advancement, as the Myriad patent made it impossible for independent laboratories to offer testing services and researchers or physicians to evaluate or develop alternative tests for BRCA1 and BRCA2.
Future of Gene Patents: The future of gene patents is shaped by courts worldwide, which decide whether or not naturally occurring genetic material can be legally protected, as well as if the decision concerns intellectual property or public access to healthcare. 12The scope of gene patenting would ultimately be limited by those important precedents. For example, the U. S. Supreme Court ruled in Association for Molecular Pathology v. Myriad Genetics (2013) that patents covering genetic material that has been synthetically modified would include complementary DNA (cDNA) but not naturally occurring DNA sequences. In the same vein, gene patents must first be isolated, modified, and used in an industrial setting in accordance with stringent guidelines established by the European Patent Office (EPO) in accordance with the Biotech Directive (98/44/EC).
Despite this, there are still disagreements about gene patent laws around the globe, and discussions about whether gene-editing technologies like CRISPR can be covered by patents have not abated. Because U. S. and EU courts have differing views on who has primary rights with relation to CRISPR technology, legal differences have resulted in a disorganised state of intellectual property. Possible legislative amendments aimed to reduce violence against genetic information monopolisation, standardise patent eligibility conditions, and encourage more biotechnology and medical research. Adopting a globally accepted, WTO/WIPOsupervised genetic patenting framework is one recommended course of action. Giving governments the authority to enforce compulsory licensing, which would allow them to override gene patents where doing so would benefit the public's health, is another proposed legal reform.
Given the ongoing bioethical issues regarding gene patents, numerous regulatory bodies and bioethics committees have developed ethical guidelines to govern biotech patenting activities. Human DNA is irrelevant and shouldn't be regarded as private property, according 12 Francis S Collins and others, ‘A Vision for the Future of Genomics Research’ (2003) 422 Nature 835 accessed 12 January 2025. to organisations like UNESCO, WHO, and national bioethics councils, unless it has undergone significant scientific modification. The human genome is "the heritage of mankind," according to the 1997 Universal Declaration of the Human Genome and Human Rights, and as such, companies shouldn't be the only proprietors of genetic resources.
Some ethical rules for structuring biotech patents are listed below: • Prohibiting patents on naturally occurring human genes but permitting patents on genetically edited sequences with proven industrial applications. • Preventing barriers to innovation caused by overly broad patents and making sure genetic research remains collaborative and open. Enhancing informed consent policies and making sure that, in the event of research, it is obtained from human genetic resources in an understandable and moral manner; requiring mandatory licensing measures that will give developing nations fair access to genetic technologies. To stop patent holders from using genetic discoveries for monopolistic control, bioethics appraisal committees and regulatory agencies have a sizable pool for keeping an eye on genetic patent applications.
Actually, organisations like the Nuffield Council on Bioethics (UK) and the EGE have been vocal supporters of changing the legislation to stop unethical gene patenting. The difficulty facing gene patent law is striking the correct balance between profit-driven innovation and the common good. While biotechs contend that patents are essential for funding chains for genetic research, critics contend that excessive patenting will impede scientific advancement and access to medications. The BRCA gene patenting dispute demonstrates how DNA monopolisation can result in increased diagnostic prices and guarantee that access to lifesaving treatments is denied. Governments, academic institutions, and research centres all have a part in maintaining this balance. The evil of gene monopolisation would be curbed by price limits and legislation requiring licenses.
Because of publicly sponsored open-access genetic research projects like the Human Genome Project, important genetic information is maintained accessible to researchers worldwide. Patent-sharing arrangements and cooperative biotech research are two other ways that academic institutions and research centres support the balance. Instead of rigorous university commercialisation, knowledge-sharing methods are promoted that would enable the development of genetic research procedures for the benefit of the general public and scientific societies. Governments must enact new laws and regulations to ensure that all genetic advances are supported while avoiding corporate monopolies if genetics advancement is to have any impact on the developed world's model of profit-driven exclusivity.
Conclusion: Gene patents have significant economic, ethical, and legal implications for biotechnology, medical research, and healthcare access. Case law, such as Diamond v. Chakrabarty (1980) and Association for Molecular Pathology v. Myriad Genetics (2013), has shown the historical developments of gene patenting, with courts drawing lines in patent rights against nature discoveries. The TRIPS Agreement and national legal frameworks in the US, EU, and India reflect different approaches to gene patents. Some jurisdictions prohibit patents on genes naturally existing, while others endorse patents over genetic sequences, whether modified or not. Gene patents create monopolistic access barriers, increase the cost of genetic tests and lifesaving therapies, and dissuade investment in genetic research and drug development.
The Myriad Genetics example shows how exclusive patent claim over BRCA genes initially limited access to breast cancer diagnoses, but competition led to lower costs and improved accessibility following the Supreme Court's decision. One of the issues raised by CRISPR patent conflicts is the moral application of gene-editing technologies, which exacerbates the perennial battles between academic institutions and private companies. Ethical dilemmas on gene patenting are yet to be resolved, particularly concerning public health and human rights. India's stringent patent laws under the Indian Patents Act, 1970, support the
1997 Universal Declaration on the Human Genome and Human Rights, which states that
human DNA should never be owned by private individuals. Organizations like the World Health Organization warn against excessive patenting that may deepen global health inequalities, and the right to health has become one of the main ways to argue against the commercialization of genetic material. To balance commercial interests with scientific enquiry, researchers and policymakers should consider standardizing gene patent laws worldwide under WIPO, promoting patent pools and open science, enhancing protections against patent monopolies for public health, developing clear regulatory frameworks for gene-editing technologies like CRISPR-Cas9, and conducting empirical research on the long-term financial impacts of gene patents. In conclusion, gene patents have significant economic, ethical, and legal implications for biotechnology, medical research, and healthcare access.
Future studies should investigate how gene patents affect medication costs, alternative patent models' viability from an economic standpoint, the effects of synthetic biology and CRISPR on current patent frameworks, and how developing nations are handling the situation with gene patents. The gene patent controversy is a complex and evolving issue that involves ethical, scientific, and legal considerations. While intellectual property rights can promote biotech innovation, they also present issues with pricing, accessibility, and monopolization. The Myriad Genetics case established a precedent for the availability of basic genetic information for study and therapeutic application. The CRISPR patent battle highlights the legal challenges of patenting gene-editing technology, as gene-editing medicines, personalized medicine, and synthetic DNA continue to progress.
Emerging biotechnologies like CRISPR-Cas9, gene therapy, and synthetic biology blur the lines between naturally occurring genetic material and human-made instances. Patentability of genetically modified sequences remains under serious conflict, as widespread commercialization could cut off access to important gene-based research and treatment. Additionally, concerns persist in the industry that gene patents will legally thwart research, making it difficult for small biotech firms, academic institutions, and scientists to develop copyrighted sequences without costly licensing arrangements. To benefit society from genetic research, a multi-stakeholder approach is needed, involving government, academia, and research institutions. Government participation should be involved in drafting patent laws that balance public health implications with innovation.
Patent policies should place restrictions on monopolistic control of life-saving medical developments while encouraging proper commercialization of genetic findings. Public funding for open access genetic studies, regulation of fees charged for patent licensing, and compulsory licensing mechanisms should be enforced to facilitate affordable delivery of patent gene-based treatments. Universities and research institutions should also play an important role in developing patent-sharing models that respect ethical conduct in research. Gene patenting will be best served by a careful consideration of economic interests, moral obligation, and scientific advancement. Strengthening moral standards and ensuring that patents work toward innovation and common good will help address genetic ownership issues.
The world community can carve a gene patent system that serves humanity by supporting just licensing practices, improving transparency in genetic research, and ensuring accessibility to the biotechnology industry.
References/Bibliography
1. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013).
2. Diamond v. Chakrabarty, 447 U.S. 303 (1980).
3. Bayh-Dole Act, 35 U.S.C. §§ 200–212 (1980).
4. Directive 98/44/EC, of the European Parliament and of the Council of 6 July 1998 on
the Legal Protection of Biotechnological Inventions, 1998 O.J. (L 213) 13.
5. The Patents Act, No. 39 of 1970, § 3(c) & § 3(d) (India).
6. Universal Declaration on the Human Genome and Human Rights, UNESCO, Nov. 11,
1997.
7. World Health Organization, Genomics and World Health (2002).
8. Nuffield Council on Bioethics, The Ethics of Patenting DNA (2002).
9. European Group on Ethics in Science and New Technologies, Ethical Aspects of
Patenting Inventions Involving Human Stem Cells, Opinion No. 16 (May 2002).
10. Utility Examination Guidelines, 66 Fed. Reg. 1092 (Jan. 5, 2001) (to be codified at 37
C.F.R. pt. 1).
11 Timothy Caulfield, Human Gene Patents
Ethical and Legal Issues, 1 Nat. Rev. Genet.
227 (2000).
12. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The
Anticommons in Biomedical Research, 280 Science 698 (1998).
13 Arti K. Rai, Addressing the Patent Gold Rush
The Role of Deference to PTO Patent Denials, 151 U. Pa. L. Rev. 1901 (2003).
14. Rebecca S. Eisenberg, Re-examining the Role of Patents in Promoting Access to
Genetic Innovations, 38 J.L. Med. & Ethics 324 (2010).
15 Robert Cook-Deegan, The Gene Wars
Science, Politics, and the Human Genome (W.W. Norton 1994).
16. National Human Genome Research Institute, The Human Genome Project Completion
and its Impact, https://www.genome.gov.
17. WHO Commission on Intellectual Property Rights, Innovation and Public Health,
Public Health, Innovation and Intellectual Property Rights (2006).
18. UNESCO International Bioethics Committee, Reports on the Human Genome and
Human Rights, various editions.
19 Namrata Choudhury, Patentability of Biotechnological Inventions
A Comparative Study, 18 J. Intell. Prop. Rts. 456 (2013) (India).